Q2 EPS Estimates for Denali Therapeutics Cut by B. Riley

Denali Therapeutics Inc. (NASDAQ:DNLI) – Investment analysts at B. Riley lowered their Q2 2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research report issued on Wednesday, March 5th. B. Riley analyst M. Mamtani now anticipates that the company will earn ($0.80) per share for the quarter, down from their previous forecast of ($0.79). B. Riley has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. B. Riley also issued estimates for Denali Therapeutics’ FY2025 earnings at ($2.72) EPS, FY2026 earnings at ($2.48) EPS, FY2027 earnings at ($1.38) EPS and FY2028 earnings at ($2.05) EPS.

Other equities research analysts have also issued reports about the stock. William Blair reissued an “outperform” rating on shares of Denali Therapeutics in a report on Friday, February 28th. Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a report on Tuesday, February 11th. They issued a “buy” rating and a $31.00 price objective on the stock. Baird R W raised Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. JPMorgan Chase & Co. cut their price target on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, January 7th. Finally, Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a research report on Monday, December 16th. Two analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.57.

Denali Therapeutics Trading Down 0.2 %

NASDAQ:DNLI opened at $16.27 on Friday. The company’s 50 day moving average is $20.98 and its two-hundred day moving average is $24.41. The company has a market cap of $2.34 billion, a PE ratio of -5.89 and a beta of 1.43. Denali Therapeutics has a twelve month low of $14.01 and a twelve month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.08.

Hedge Funds Weigh In On Denali Therapeutics

Large investors have recently made changes to their positions in the stock. Principal Financial Group Inc. lifted its stake in Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after purchasing an additional 149,939 shares in the last quarter. AIA Group Ltd raised its holdings in shares of Denali Therapeutics by 7.9% in the 3rd quarter. AIA Group Ltd now owns 74,815 shares of the company’s stock valued at $2,179,000 after buying an additional 5,471 shares during the period. Assetmark Inc. lifted its stake in Denali Therapeutics by 18.0% during the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after acquiring an additional 580 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Denali Therapeutics by 163.7% during the 3rd quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock worth $1,162,000 after acquiring an additional 24,767 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its holdings in Denali Therapeutics by 6.4% during the 3rd quarter. Thrivent Financial for Lutherans now owns 138,862 shares of the company’s stock valued at $4,045,000 after acquiring an additional 8,358 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the sale, the director now owns 107,976 shares in the company, valued at $2,257,778.16. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ryan J. Watts sold 29,266 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the completion of the transaction, the chief executive officer now directly owns 260,721 shares in the company, valued at approximately $5,271,778.62. This trade represents a 10.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,940 shares of company stock worth $973,442 in the last ninety days. 7.90% of the stock is owned by insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.